These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19811240)

  • 1. Cardiovascular aspects of menopausal hormone replacement therapy.
    Rosano GM; Vitale C; Fini M
    Climacteric; 2009; 12 Suppl 1():41-6. PubMed ID: 19811240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.
    Rosano GM; Maffei S; Andreassi MG; Vitale C; Vassalle C; Gambacciani M; Stramba-Badiale M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM; Vitale C; Fini M
    Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy and cardioprotection: the end of the tale?
    Rosano GM; Vitale C; Silvestri A; Fini M
    Ann N Y Acad Sci; 2003 Nov; 997():351-7. PubMed ID: 14644842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of the month. Benefit/risk balance of postmenopausal estrogen-progestin treatment in peril in the Women's Health Initiative study: practical attitude of the clinician].
    Gaspard U; van den Brûle F; Pintiaux A; Foidart JM
    Rev Med Liege; 2002 Aug; 57(8):556-62. PubMed ID: 12405030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
    Lemay A
    J Obstet Gynaecol Can; 2002 Sep; 24(9):711-5. PubMed ID: 12360366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Postmenopausal hormone replacement therapy and the cardiovascular system].
    Yildirir A
    Turk Kardiyol Dern Ars; 2010 Mar; 38 Suppl 1():32-40. PubMed ID: 21491714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular effects of estrogenic menopausal hormone therapy.
    Reslan OM; Khalil RA
    Rev Recent Clin Trials; 2012 Feb; 7(1):47-70. PubMed ID: 21864249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy and stroke.
    Billeci AM; Paciaroni M; Caso V; Agnelli G
    Curr Vasc Pharmacol; 2008 Apr; 6(2):112-23. PubMed ID: 18393913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic features of menopausal and postmenopausal applicants for life insurance.
    Schiefeling M
    J Insur Med; 1996; 28(1):27-34. PubMed ID: 10172866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal hormone therapy: lessons from observational and randomized studies.
    Rosano GM; Vitale C; Lello S
    Endocrine; 2004 Aug; 24(3):251-4. PubMed ID: 15542893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menopause and the Heart.
    Nkonde-Price C; Bender JR
    Endocrinol Metab Clin North Am; 2015 Sep; 44(3):559-64. PubMed ID: 26316243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Stramba-Badiale M
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menopausal hormone therapy: currently no evidence for cardiac protection.
    Wenger NK
    Pediatr Blood Cancer; 2005 Jun; 44(7):625-9. PubMed ID: 15747336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.
    Naftolin F; Taylor HS; Karas R; Brinton E; Newman I; Clarkson TB; Mendelsohn M; Lobo RA; Judelson DR; Nachtigall LE; Heward CB; Hecht H; Jaff MR; Harman SM;
    Fertil Steril; 2004 Jun; 81(6):1498-501. PubMed ID: 15193467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease.
    Mehta JM; Chester RC; Kling JM
    J Womens Health (Larchmt); 2019 May; 28(5):705-711. PubMed ID: 30484736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
    Speroff L
    Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.